Rare Disease CME/CE Online Courses

myCME Your search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

The Pathologist’s Perspective: The Importance of Ring Sideroblast Quantification and Evaluation in Myelodysplastic Syndromes

Ring Sideroblast Quantification in Myelodysplastic Syndromes | myCME

AMA PRA Category 1 Credit(s)^TM

1.50 CME: Symposium on pathology of MDS-RS includes a cross-disciplinary interview enhanced by infographics and pathologist pocket guide. Exp 4/28/2023

Minimizing Lung Consequences of Alpha-1 Antitrypsin Deficiency (AATD): Facilitating Prompt Diagnosis and Appropriate Treatment

Lung Consequences of Alpha-1 Antitrypsin Deficiency | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AAPA Category I CME Credit

1.00 CME CE: Interactive, case-based approach to diagnosis and appropriate management of individuals with Alpha-1 antitrypsin deficiency (AATD). Exp 6/9/23

Improving Diagnosis and Clinical Monitoring of Acid Sphingomyelinase Deficiency

Improving Diagnosis and Clinical Monitoring of ASMD | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.00 CME CE: Experts Drs. Margaret McGovern and Pramod Mistry review the diagnosis and treatment of acid sphingomyelinase deficiency. Exp 5/27/23

Updates in Duchenne’s Muscular Dystrophy: A Focus on Emerging Gene Therapy

Emerging Gene Therapy in Duchenne’s MD | myCME

AMA PRA Category 1 Credit(s)^TM

1.00 CME: Case that explains genetic causes of DMD and discusses preliminary outcomes of 3 clinical trials using gene therapy to treat DMD. Exp 12/31/22

Systemic Sclerosis-Associated Interstitial Lung Disease: Making Connections, Elevating Care

Systemic Sclerosis-Associated Interstitial Lung Disease | myCME

AMA PRA Category 1 Credit(s)^TM

2.00 CME: 5 learning modules in video/audio/whiteboard format modeled after subway map, allowing for self-directed educational experience. Exp 2/28/23

A New Era in Relieving the Burden and Improving Health Outcomes of Children with Growth Hormone Deficiency

Outcomes of Children with Growth Hormone Deficiency | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

2.00 CME: Video/audio/whiteboard format modeled after subway map, allowing for structured learning pathway or self-directed education. Exp 3/18/23

Advances in Beta Thalassemia: Reducing Transfusion Burden With Novel Molecular Therapies

Beta Thalassemia Advances : Reducing Transfusion Burden | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: This interactive e-journal article covers pathophysiology, diagnostic criteria, clinical trial data, and transition preparedness strategies. Exp 3/11/2023

Targeting Disease Pathophysiology in Prurigo Nodularis – Now and in the Near Future

Targeting Disease Mechanisms in Prurigo Nodularis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Current PN therapies often do not meet treatment goals. Emerging, targeted treatment strategies are on the horizon for PN patients. Exp 3/30/23

Healthcare Burden of Prurigo Nodularis: Implications for Targeted Treatment Approaches

The Burden of Prurigo Nodularis: New Targeted Treatments | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Prurigo nodularis results in high personal and socioeconomic costs. Targeted therapies may alleviate some of these. Learn more! Exp. 3/30/2023

Novel Mechanisms Mean Novel Management in Prurigo Nodularis: An Interactive Infographic Activity

Novel Mechanisms in Prurigo Nodularis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE There are limited treatment options for PN. This interactive activity provides an overview of how emerging therapies target its underlying pathophysiology. Exp 3/31/23

A New Dawn for Better Outcomes in Patients With Idiopathic Hypersomnia: New Data, New Guidance, New Treatments

Idiopathic Hypersomnia: New Data, New Guidance, New Treatments | myCME

AMA PRA Category 1 Credit(s)^TM

1.50 CME: Learn how to use updated guidelines and a recently approved medication to diagnose and comprehensively manage Idiopathic Hypersomnia. Exp 7/29/23

Gene Therapy for X-Linked Retinitis Pigmentosa: Implications for Clinical Practice Right Now

Gene Therapy for XLRP: Implications for Clinical Practice | myCME

AMA PRA Category 1 Credit(s)^TM, COPE CE Credit(s)

1.00 CME COPE: XLRP: Diagnosis, genetic testing, clinical trials, and support. Exp 6/30/23